<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Dr-Reddy-s-Laboratories-Ltd-Sponsored-ADR-US2561352038">Dr. Reddy&#39;s Laboratories Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4861551-dr-reddys-laboratories-limited-rdy-q3-2026-earnings-call-transcript">Dr. Reddy&#39;s Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript</a>
    </div>

      <div class="me-0 me-md-5">
        Dr. Reddy&#39;s Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Dr-Reddy-s-Laboratories-Ltd-Sponsored-ADR-US2561352038">Dr. Reddy&#39;s Laboratories Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260114267679/en/Dr.-Reddy%E2%80%99s-Announces-the-First-to-Market-Launch-of-Olopatadine-Hydrochloride-Ophthalmic-Solution-USP-0.7-OTC-the-Generic-Equivalent-of-Extra-Strength-Pataday%C2%AE-Once-Daily-Relief-in-the-U.S./">Dr. Reddy&#39;s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.</a>
    </div>

      <div class="me-0 me-md-5">
        HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Antihistamineeyedrop--Dr. Reddy&#39;s launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Strength Pataday® Once Daily Relief.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Dr-Reddy-s-Laboratories-Ltd-Sponsored-ADR-US2561352038/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>